Drug halts complications in heparin-intolerant patients
Recent Phase III study results on argatroban, an alternative anticoagulant to heparin, shows the drug significantly reduces development of new thrombosis and death due to thrombosis in patients with heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia and thrombosis syndrome (HITTS). The study was conducted at the Loyola University Medical Center in San Diego.
The study showed a 73% reduction of new thrombosis in the HIT argatroban-treated population and a 54% reduction of new thrombosis in the HITTS argatroban-treated population. Death due to thrombosis was reduced by 100% and 86% for HIT and HITTS patients, respectively.
While there was no increase in major bleeding, the trial also demonstrated a 129% increase in platelet counts in HIT patients and 198% in HITTS patients.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content